OBJECTIVE:Gender differences are a well-known clinical characteristic of Parkinson's disease (PD). In-vivo imaging studies demonstrated that women have greater striatal dopamine transporter (DAT) activity than do men, both in the normal population and in PD patients. We hypothesize that women exhibit more rapid aging-related striatal DAT reduction than do men, as the potential neuroprotective effect of estrogen wanes with age. METHODS:This study included 307 de novo PD patients (152 men and 155 women) who underwent DAT scans for an initial diagnostic work-up. Gender differences in age-related DAT decline were assessed in striatal sub-regions using linear regression analysis. RESULTS:Female patients exhibited greater DAT activity compared ...
Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzh...
Background: Investigation of sex-related motor and non-motor differences and biological markers in P...
Objective: To evaluate the sex differences in cognitive course over 4 years in Parkinson’s disease (...
Objective Gender differences are a well-known clinical characteristic of Parkinson’s disease (PD). I...
ObjectiveaaGender differences are a well-known clinical characteristic of Parkinson’s disease (PD). ...
Objective: To investigate gender differences in basic disease characteristics, motor deterioration a...
OBJECTIVE: To investigate gender differences in basic disease characteristics, motor deterioration a...
Background and objective: Brain atrophy and cognitive impairment in neurodegenerative diseases are i...
This study aimed to investigate the potential beneficial effects of estrogen on nigrostriatal dopami...
Parkinson's disease (PD) is characterized by heterogeneity in clinical syndromes, prognosis, and pat...
AbstractParkinson’s disease (PD) displays a greater prevalence and earlier age at onset in men. This...
Background: In Parkinson's disease (PD), neurodegeneration of dopaminergic sys...
One striking observation in Parkinson’s disease (PD) is the remarkable gender difference in incidenc...
Introduction: A bundle of evidence indicates that biological sex is an important factor for clinical...
Item does not contain fulltextGender differences in brain dopaminergic activity have been variably r...
Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzh...
Background: Investigation of sex-related motor and non-motor differences and biological markers in P...
Objective: To evaluate the sex differences in cognitive course over 4 years in Parkinson’s disease (...
Objective Gender differences are a well-known clinical characteristic of Parkinson’s disease (PD). I...
ObjectiveaaGender differences are a well-known clinical characteristic of Parkinson’s disease (PD). ...
Objective: To investigate gender differences in basic disease characteristics, motor deterioration a...
OBJECTIVE: To investigate gender differences in basic disease characteristics, motor deterioration a...
Background and objective: Brain atrophy and cognitive impairment in neurodegenerative diseases are i...
This study aimed to investigate the potential beneficial effects of estrogen on nigrostriatal dopami...
Parkinson's disease (PD) is characterized by heterogeneity in clinical syndromes, prognosis, and pat...
AbstractParkinson’s disease (PD) displays a greater prevalence and earlier age at onset in men. This...
Background: In Parkinson's disease (PD), neurodegeneration of dopaminergic sys...
One striking observation in Parkinson’s disease (PD) is the remarkable gender difference in incidenc...
Introduction: A bundle of evidence indicates that biological sex is an important factor for clinical...
Item does not contain fulltextGender differences in brain dopaminergic activity have been variably r...
Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzh...
Background: Investigation of sex-related motor and non-motor differences and biological markers in P...
Objective: To evaluate the sex differences in cognitive course over 4 years in Parkinson’s disease (...